EIF4A3-dependent nonsense-mediated decay buffers AML1-ETO9a dosage and modulates outcome in t(8;21) acute myeloid leukemia
A protein marker that suppresses a dangerous leukemia variant predicts better survival in certain acute myeloid leukemia patients, offering hope for more tailored treatment decisions.
This study identifies RNA surveillance via nonsense-mediated mRNA decay (NMD) as an isoform-specific checkpoint controlling the oncogenic AML1-ETO9a (AE9a) splice variant in t(8;21) AML; EIF4A3 overexpression reduces AE9a protein, restrains leukemic growth, and enhances chemosensitivity. Clinical data show high EIF4A3 expression associates with improved survival exclusively in t(8;21) AML, providing a mechanistic explanation for outcome heterogeneity and identifying a new prognostic biomarker.
What the study was
- Study design
- basic_and_translational_science
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Leukemia
Why it surfaced
High-impact Leukemia publication linking RNA surveillance to oncogene dosage control in AML with direct patient outcome correlation; EIF4A3 is a tractable target for idarubicin sensitization in t(8;21) AML. Score 8 reflects strong translational mechanistic clarity (E=2) and direct AML clinical relevance despite preclinical design (D=1).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.